SB525334 is a selective inhibitor of transforming growth factor-?? receptor I (ALK5, TGF-??RI) (IC50 = 14.3 nM). Inhibits TGF-??1-induced smad2/3 nuclear localization and TGF-??RI-induced mRNA expression in kidney cells
More Information Supplier PageSB525334 is a selective inhibitor of transforming growth factor-?? receptor I (ALK5, TGF-??RI) (IC50 = 14.3 nM). Inhibits TGF-??1-induced smad2/3 nuclear localization and TGF-??RI-induced mRNA expression in kidney cells
More Information Supplier PageSB525334 is a selective inhibitor of transforming growth factor-?? receptor I (ALK5, TGF-??RI) (IC50 = 14.3 nM). Inhibits TGF-??1-induced smad2/3 nuclear localization and TGF-??RI-induced mRNA expression in kidney cells
More Information Supplier PageSB525334 is a selective inhibitor of transforming growth factor-?? receptor I (ALK5, TGF-??RI) (IC50 = 14.3 nM). Inhibits TGF-??1-induced smad2/3 nuclear localization and TGF-??RI-induced mRNA expression in kidney cells
More Information Supplier PageSB525334 is a selective inhibitor of transforming growth factor-?? receptor I (ALK5, TGF-??RI) (IC50 = 14.3 nM). Inhibits TGF-??1-induced smad2/3 nuclear localization and TGF-??RI-induced mRNA expression in kidney cells
More Information Supplier PageSB 431542 is a potent and specific inhibitor of transforming growth factor-?? superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 .
More Information Supplier PageSB 431542 is a potent and specific inhibitor of transforming growth factor-?? superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 .
More Information Supplier PageSB 431542 is a potent and specific inhibitor of transforming growth factor-?? superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 .
More Information Supplier PageSB 743921, a second generation KSP inhibitor, is a highly potent and active therapeutic in preclinical models of cancer.
More Information Supplier PageSB 743921, a second generation KSP inhibitor, is a highly potent and active therapeutic in preclinical models of cancer.
More Information Supplier Page
